Article Text

AB0485 Primary antiphospholipid syndrome: maternal and fetal outcome
  1. C Otaduy1,
  2. PB Alba1,
  3. CA Gobbi1,
  4. A Alvarez2,
  5. A Albiero3,
  6. EH Albiero1,
  7. ML Propato2,
  8. MA Yorio1
  1. 1Rheumatology, Cόrdoba State University
  2. 2Rheumatology, Hospital Materno Neonatal
  3. 3Rheumatology, Hospital Cόrdoba, Cόrdoba, Argentina


Background Antiphospholipid antibodies (APLAs) have been associated with pregnancy loss and other obstetric complications, such as pre-eclampsia, fetal growth restriction and preterm delivery.

Objectives The purpose of this work is to evaluate maternal and fetal pregnancy outcome in Primary Antiphospholipid Syndrome (PAPS).

Methods We retrospectively studied PAPS patients according to Sydney Criteria who are attended to Materno Neonatal Hospital during the last 8 years. We evaluated demographic, obstetric and thrombotic clinical data. Maternal complications were evaluated: Preeclampsia, HELLP, Gestational Diabetes, Premature rupture of fetal membranes, arterial and venous thrombosis, mortality, the way of end of pregnancy, and others. Fetal outcome was evaluated as live birth, gestational age and weight at birth.

Results 96 pregnancies in 68 patients were included. Maternal mean age was 30,75 years old, 84% were from Cόrdoba city, 70.5% did not have health insurance, and they have mean previous pregnancies of 4 with 1 live birth. Maternal complications were: Pre eclampsia in 12 patients (12.5%), Preterm delivery in 6 patients (6.25%), Premature rupture of fetal membranes in 8 (8.33%), Gestational Diabetes in 7 (7.29%), Arterial Thrombosis in 2 (2.08%), Venous thrombosis in 3 (3.12%). 33,69% have normal labour and 66,33% cesarean section. 86% of patients have live birth with mean gestational age of 36 weeks with mean weight at birth of 2.558 g and 73% of patients according to gestational age.

Table 1.

Maternal Complications

Conclusions PAPS pregnancies patients had a good maternal and fetal outcome in this study.


  1. Bertolaccini ML, Sanna G2 Recent advances in understanding antiphospholipid syndrome. F1000Res. 2016 Dec 22;5:2908. doi: 10.12688/f1000research.9717.1. eCollection 2016.

  2. Pelusa HF, Pezzarini E, Basiglio CL, Musuruana J, Bearzotti M, Svetaz MJ, Daniele SM, Bottai H, Arriaga SM. Antiphospholipid and antioangiogenic activity in females with recurrent miscarriage and antiphospholipid syndrome.Ann Clin Biochem. 2016 Sep 16. pii: 0004563216672248. [Epub ahead of print.

  3. Moroni G, Doria A, Giglio E, Tani C, Zen M, Strigini F, Zaina B, Tincani A, de Liso F, Matinato C, Grossi C, Gatto M, Castellana P, Limardo M, Meroni PL, Messa P, Ravani P, Mosca M. Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study.J Autoimmun. 2016 Nov;74:6–12. doi: 10.1016/j.jaut.2016.07.010. Epub 2016 Aug 2.


Acknowledgements We are grateful whit Secyt subsidy UNC.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.